Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02871882 · ClinicalTrials.gov registry record · Phase 2
Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT02871882: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT02871882 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02871882, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
To study the effect of an ileocolonic formulation of ox bile extract on insulin sensitivity, postprandial glycemia and incretin levels, gastric emptying, body weight and fasting serum FGF-19 (fibroblast growth factor) levels in overweight or obese type 2 diabetic subjects on therapy with DPP4 (dipeptidyl peptidase-4) inhibitors (e.g. sitagliptin) alone or in combination with metformin.
Primary Outcome
Measurement of the glucose concentration in the bloodstream 6 hours after eating a meal
Interventions
- OTHER Placebo
- RADIATION Gastric Emptying test
- OTHER Mixed Oral Glucose Tolerance test
- DRUG Conjugated bile acids sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-09-15 |
| Est. Completion | 2017-10-30 |
| Phase | Phase 2 |
What the finished NCT02871882 record still lists
NCT02871882 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02871882 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02871882 about?
NCT02871882 is a clinical study titled "Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus". To study the effect of an ileocolonic formulation of ox bile extract on insulin sensitivity, postprandial glycemia and incretin levels, gastric emptying, body weight and fasting serum FGF-19 (fibroblast growth factor) levels in overweight or obese type 2 diabetic subjects on therapy with DPP4 (dipep...
What is the current status of trial NCT02871882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-09-15. Estimated completion is 2017-10-30.
What interventions are being tested in trial NCT02871882?
The interventions under investigation include: Placebo (OTHER), Gastric Emptying test (RADIATION), Mixed Oral Glucose Tolerance test (OTHER), Conjugated bile acids sodium (DRUG).
Who is sponsoring clinical trial NCT02871882?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02871882's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI